Braingaze published a paper in GeroScience reporting on Oculomotor dynamics showing distinct condition-dependent patterns associated with AT(N) biological profiles in individuals with MCI.
Published
Signal category
Research & Knowledge
Quote
“Oculomotor dynamics show distinct, condition-dependent patterns associated with different AT(N) biological profiles in individuals with MCI, supporting their potential as a non-invasive biomarker of underlying Alzheimer’s pathology.”
— Hans Supèr|Braingaze team
Company
Braingaze
Technology-driven early-stage detection and therapeutic support tools for ADHD, ASD, Alzheimer's Disease. CE Marked.
- Industry
- Medical Equipment Manufacturing
- Location
- Mataro, ES
- Company size
- 7 employees
Braingaze develops digital health solutions to detect, diagnose and treat cognitive disorders and diseases such as ADHD and Alzheimer's disease. Our solutions leverage brain circuits that connect small involuntary eye movements as a marker and enabler of cognitive processing. We call this eye movement cognitive vergence; whose use has been patented worldwide. Braingaze solutions have been used for years in leading clinics seeking better outcomes for their patients. Braingaze is powered by an international, interdisciplinary team of scientists (clinical, mathematicians and artificial intelligence experts), as well as product developers and entrepreneurs.
Founded 2013